Ingrid Swanson Pultz
Ingrid Swanson Pultz is CTO and Translational Advisor at Mopac Biologics, and also serves as Chief Technology Officer at Mopac and as a Protein Design Researcher at the University of Washington.
Insights from Uncommon Thinkers: How these innovators found novel approaches in their fields
This week on the GeekWire Podcast, we sit down with some of the Seattle region’s “Uncommon Thinkers” — inventors, scientists, technologists and entrepreneurs transforming industries and driving positive change in the world. We recorded the episode on location, backstage at the GeekWire Gala, where we recognized five Uncommon Thinkers through this annual awards program, presented in partnership with Greater Seattle Partners. Speaking on the episode are: Uri Shumlak, co-founder and chief scientist at Zap Energy, a physicist leading a team in pursuit of fusion energy, taking a different approach from others in the field. Read the profile. Ingrid Swanson Pultz…
Takeda buys Seattle startup PvP Biologics for up to $330M, will advance TAK-062 into Phase 2
Japanese pharmaceutical Takeda acquired Seattle biotech PvP Biologics for up to $330 million in late February, taking over its TAK-062 (Kuma062) program and all clinical and manufacturing activities while laying off PvP staff. Takeda plans to run phase 2 trials of the enzyme-based celiac disease treatment that PvP developed after earlier funding of $35 million supported phase 1 work.
Organizations
-
Mopac Chief Technology Officer · current
-
Mopac Biologics CTO and Translational Advisor · current
-
University of Washington Protein Design Researcher · current
